한글목차

개요

류마티스 관절염 치료제 시장은 2023-2028년 160억 4,512만 달러, 예측 기간 중 CAGR은 7.5%로 성장할 것으로 예측되고 있습니다.

류마티스 관절염 치료제 시장의 전체적인 분석, 시장 규모·예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 다룬 벤더 분석 등을 제공합니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공하고 있습니다. 류마티스 관절염(RA)의 증례의 증가, 류마티스 전문의의 증가, 진단 방법 개선, RA에 대한 적정 가격의 생물학적 제제의 필요성 등이 시장을 촉진하고 있습니다.

향후 수년간 류마티스 관절염 치료제 시장 성장을 촉진하는 주요인의 하나로 RA에 대한 의료보험 제도의 제공을 들고 있습니다. 또한 RA 치료에서 생물학적 제제/바이오시밀러의 사용 및 RA 치료에서 유전자 치료의 사용은 시장의 큰 수요로 연결됩니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 에코시스템

제3장 시장 규모

• 시장의 정의
• 시장 부문 분석
• 시장 규모 2023
• 시장 전망 2023-2028

제4장 시장 규모 실적

• 세계의 류마티스 관절염 치료제 시장 2018-2022
• 약제 클래스별 부문 분석 2018-2022
• 유형별 부문 분석 2018-2022
• 지역별 부문 분석 2018-2022
• 국가별 부문 분석 2018-2022

제5장 Five forces 분석

• Five Forces 요약
• 구매자의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁의 위협
• 시장 현황

제6장 시장 세분화 : 약제 클래스별

• 시장 부문
• 비교 : 약제 클래스별
• 질환 조절성 항류마티스약 : 시장 규모와 예측 2023-2028
• 비스테로이드성 항염증약 : 시장 규모와 예측 2023-2028
• 코르티코스테로이드 : 시장 규모와 예측 2023-2028
• 시장 기회 : 약제 클래스별

제7장 시장 세분화 : 유형별

• 시장 부문
• 비교 : 유형별
• 생물제제 : 시장 규모와 예측 2023-2028
• 저분자 : 시장 규모와 예측 2023-2028
• 시장 기회 : 유형별

제8장 고객 상황

• 고객 상황의 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측 2023-2028
• 유럽 : 시장 규모와 예측 2023-2028
• 아시아 : 시장 규모와 예측 2023-2028
• 세계의 기타 지역 : 시장 규모와 예측 2023-2028
• 미국 : 시장 규모와 예측 2023-2028
• 영국 : 시장 규모와 예측 2023-2028
• 중국 : 시장 규모와 예측 2023-2028
• 독일 : 시장 규모와 예측 2023-2028
• 프랑스 : 시장 규모와 예측 2023-2028
• 시장 기회 : 지역 상황별

제10장 촉진요인, 과제 및 동향

• 시장 촉진요인
• 시장이 해결해야 할 과제
• 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란의 상황
• 업계의 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• AbbVie Inc.
• Amgen Inc.
• Bristol Myers Squibb Co.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Genor Biopharma Holdings Ltd.
• Gilead Sciences Inc.
• Johnson and Johnson
• Kangstem Biotech Co. Ltd.
• Novartis AG
• Oryn Therapeutics
• Pfizer Inc.
• Sanofi
• Sorrento Therapeutics Inc.
• UCB SA

제13장 부록

영문목차

Abstract

The rheumatoid arthritis drugs market is forecasted to grow by USD 16045.12 mn during 2023-2028, accelerating at a CAGR of 7.5% during the forecast period. The report on the rheumatoid arthritis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising cases of RA and focus on increasing number of rheumatologists, availability of improved diagnostic modalities, and need for affordable biologics for RA.

Technavio's rheumatoid arthritis drugs market is segmented as below:

By Drug Class

• Disease-modifying anti-rheumatic drugs
• Nonsteroidal anti-inflammatory drugs
• Corticosteroids

By Type

• Biologics
• Small Molecules

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the health plan offerings for RA as one of the prime reasons driving the rheumatoid arthritis drugs market growth during the next few years. Also, use of biologics/biosimilars for treatment of RA and use of gene therapy for RA treatment will lead to sizable demand in the market.

The report on the rheumatoid arthritis drugs market covers the following areas:

• Rheumatoid arthritis drugs market sizing
• Rheumatoid arthritis drugs market forecast
• Rheumatoid arthritis drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading rheumatoid arthritis drugs market vendors that include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor Biopharma Holdings Ltd., Gilde Healthcare, Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA. Also, the rheumatoid arthritis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global rheumatoid arthritis drugs market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global rheumatoid arthritis drugs market 2018 - 2022 ($ million)
• 4.2 Drug Class Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
• 4.3 Type Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

• 6.1 Market segments
• Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)
• 6.2 Comparison by Drug Class
• Exhibit 32: Chart on Comparison by Drug Class
• Exhibit 33: Data Table on Comparison by Drug Class
• 6.3 Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028
• Exhibit 34: Chart on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
• 6.4 Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028
• Exhibit 38: Chart on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
• 6.5 Corticosteroids - Market size and forecast 2023-2028
• Exhibit 42: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
• Exhibit 43: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
• Exhibit 44: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
• 6.6 Market opportunity by Drug Class
• Exhibit 46: Market opportunity by Drug Class ($ million)
• Exhibit 47: Data Table on Market opportunity by Drug Class ($ million)

7 Market Segmentation by Type

• 7.1 Market segments
• Exhibit 48: Chart on Type - Market share 2023-2028 (%)
• Exhibit 49: Data Table on Type - Market share 2023-2028 (%)
• 7.2 Comparison by Type
• Exhibit 50: Chart on Comparison by Type
• Exhibit 51: Data Table on Comparison by Type
• 7.3 Biologics - Market size and forecast 2023-2028
• Exhibit 52: Chart on Biologics - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on Biologics - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on Biologics - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Biologics - Year-over-year growth 2023-2028 (%)
• 7.4 Small Molecules - Market size and forecast 2023-2028
• Exhibit 56: Chart on Small Molecules - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Small Molecules - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Small Molecules - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Small Molecules - Year-over-year growth 2023-2028 (%)
• 7.5 Market opportunity by Type
• Exhibit 60: Market opportunity by Type ($ million)
• Exhibit 61: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 UK - Market size and forecast 2023-2028
• Exhibit 87: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.9 China - Market size and forecast 2023-2028
• Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.10 Germany - Market size and forecast 2023-2028
• Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.11 France - Market size and forecast 2023-2028
• Exhibit 99: Chart on France - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on France - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on France - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on France - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 103: Market opportunity By Geographical Landscape ($ million)
• Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification
• 12.3 AbbVie Inc.
• Exhibit 111: AbbVie Inc. - Overview
• Exhibit 112: AbbVie Inc. - Product / Service
• Exhibit 113: AbbVie Inc. - Key news
• Exhibit 114: AbbVie Inc. - Key offerings
• 12.4 Amgen Inc.
• Exhibit 115: Amgen Inc. - Overview
• Exhibit 116: Amgen Inc. - Product / Service
• Exhibit 117: Amgen Inc. - Key offerings
• 12.5 Bristol Myers Squibb Co.
• Exhibit 118: Bristol Myers Squibb Co. - Overview
• Exhibit 119: Bristol Myers Squibb Co. - Product / Service
• Exhibit 120: Bristol Myers Squibb Co. - Key news
• Exhibit 121: Bristol Myers Squibb Co. - Key offerings
• 12.6 Eli Lilly and Co.
• Exhibit 122: Eli Lilly and Co. - Overview
• Exhibit 123: Eli Lilly and Co. - Product / Service
• Exhibit 124: Eli Lilly and Co. - Key news
• Exhibit 125: Eli Lilly and Co. - Key offerings
• 12.7 F. Hoffmann La Roche Ltd.
• Exhibit 126: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 127: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 128: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 129: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 130: F. Hoffmann La Roche Ltd. - Segment focus
• 12.8 Genor Biopharma Holdings Ltd.
• Exhibit 131: Genor Biopharma Holdings Ltd. - Overview
• Exhibit 132: Genor Biopharma Holdings Ltd. - Product / Service
• Exhibit 133: Genor Biopharma Holdings Ltd. - Key offerings
• 12.9 Gilead Sciences Inc.
• Exhibit 134: Gilead Sciences Inc. - Overview
• Exhibit 135: Gilead Sciences Inc. - Product / Service
• Exhibit 136: Gilead Sciences Inc. - Key news
• Exhibit 137: Gilead Sciences Inc. - Key offerings
• 12.10 Johnson and Johnson
• Exhibit 138: Johnson and Johnson - Overview
• Exhibit 139: Johnson and Johnson - Business segments
• Exhibit 140: Johnson and Johnson - Key news
• Exhibit 141: Johnson and Johnson - Key offerings
• Exhibit 142: Johnson and Johnson - Segment focus
• 12.11 Kangstem Biotech Co. Ltd.
• Exhibit 143: Kangstem Biotech Co. Ltd. - Overview
• Exhibit 144: Kangstem Biotech Co. Ltd. - Product / Service
• Exhibit 145: Kangstem Biotech Co. Ltd. - Key offerings
• 12.12 Novartis AG
• Exhibit 146: Novartis AG - Overview
• Exhibit 147: Novartis AG - Business segments
• Exhibit 148: Novartis AG - Key offerings
• Exhibit 149: Novartis AG - Segment focus
• 12.13 Oryn Therapeutics
• Exhibit 150: Oryn Therapeutics - Overview
• Exhibit 151: Oryn Therapeutics - Product / Service
• Exhibit 152: Oryn Therapeutics - Key offerings
• 12.14 Pfizer Inc.
• Exhibit 153: Pfizer Inc. - Overview
• Exhibit 154: Pfizer Inc. - Product / Service
• Exhibit 155: Pfizer Inc. - Key news
• Exhibit 156: Pfizer Inc. - Key offerings
• 12.15 Sanofi
• Exhibit 157: Sanofi - Overview
• Exhibit 158: Sanofi - Business segments
• Exhibit 159: Sanofi - Key news
• Exhibit 160: Sanofi - Key offerings
• Exhibit 161: Sanofi - Segment focus
• 12.16 Sorrento Therapeutics Inc.
• Exhibit 162: Sorrento Therapeutics Inc. - Overview
• Exhibit 163: Sorrento Therapeutics Inc. - Business segments
• Exhibit 164: Sorrento Therapeutics Inc. - Key offerings
• Exhibit 165: Sorrento Therapeutics Inc. - Segment focus
• 12.17 UCB SA
• Exhibit 166: UCB SA - Overview
• Exhibit 167: UCB SA - Product / Service
• Exhibit 168: UCB SA - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 169: Inclusions checklist
• Exhibit 170: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 171: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 172: Research methodology
• Exhibit 173: Validation techniques employed for market sizing
• Exhibit 174: Information sources
• 13.5 List of abbreviations
• Exhibit 175: List of abbreviations